Please login to the form below
Abraxane
This page shows the latest Abraxane news and features for those working in and with pharma, biotech and healthcare.
Tecentriq combo fails in advanced triple negative breast cancer
Tecentriq has already been approved in combination with Abraxane (nab-paclitaxel), after demonstrating a statistically significant PFS benefit and clinically meaningful improvements in OS for people with metastatic TNBC whose tumours
Latest news
-
FDA sets June decision date for Tecentriq monotherapy in NSCLC
In December, Roche also won approval for Tecentriq in combination with a chemotherapy regimen of Abraxane and carboplatin in NSCLC patients, whose cancer has metastasized and does not have EGFR or
-
Merck chases Roche with triple-negative breast cancer data for Keytruda
The actual progression-free survival (PFS) numbers for KEYNOTE-355 – which compared Keytruda plus Bristol-Myers Squibb/Celgene’s Abraxane (nab-paclitaxel), paclitaxel or gemcitabine/carboplatin to the chemo drugs given ... plus Abraxane.
-
NICE turns down Roche’s Tecentriq for triple-negative breast cancer
Tecentriq has been approved by the EMA for use in patients ineligible for surgery alongside Celgene’s Abraxane (nab-paclitaxel), and NICE estimates that around 600 of the 2, 000 women
-
Tecentriq approved in Europe for triple negative breast cancer
The scale of those revenues will very much depend on how far Roche can extend its use beyond this first setting in combination with Abraxane. ... Oncologists say there is still debate about what the best chemotherapy backbone is for anti-PD-L1 treatment
-
Triplet approvals for myeloma boost Celgene in Q2
Analysts at William Blair said Celgene’s main products grew more than expected across the board, topping their predictions by around $180m in the quarter with Abraxane (nab-paclitaxel) also performing ... Abraxane is enjoying a sales surge thanks to
More from news
Approximately 14 fully matching, plus 39 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is
-
Chinese biotech’s global ambitions
Meanwhile, BeiGene entered into a strategic global collaboration with Celgene in 2017, gaining the rights to Celgene’s Abraxane Revlimid and Vidaza in China, while Celgene gained an option to market
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Marketing strategy in complex environments
cells. A good example of this is the combined use of Abraxane and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas – Abraxane helps to inhibit cancer cell growth, and
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- bluebird bio’s beti-cel accepted for priority review by FDA
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
- Onyx Health Announces Two Top Appointments
- Omicron prompts global action
- Novo Nordisk growth takes a hit with China deal
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- AstraZeneca officially opens new R&D facility in UK
- Biogen hands out $120m upfront for Remedy stroke drug
- China backs use of Roche’s Actemra for coronavirus
PMHub
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
